Polymyositis and dermatomyositis laboratory findings: Difference between revisions
| Line 38: | Line 38: | ||
{| class="wikitable" | {| class="wikitable" | ||
!Autoantibody | !Autoantibody | ||
!Antigen | |||
!Association | !Association | ||
!Percentage | !Percentage | ||
|- | |- | ||
|Histidyl-tRNA synthetase (anti-Jo-1) | |Histidyl-tRNA synthetase (anti-Jo-1) | ||
| | |||
| | | | ||
* Antisynthetase syndrome | * Antisynthetase syndrome | ||
| Line 49: | Line 51: | ||
|- | |- | ||
|Chromodomain helicase DNA binding protein 4 (Mi-2) | |Chromodomain helicase DNA binding protein 4 (Mi-2) | ||
| | |||
| | | | ||
* Severe dermatomyositis rash without significant lung involvement | * Severe dermatomyositis rash without significant lung involvement | ||
| Line 54: | Line 57: | ||
|- | |- | ||
|Signal recognition particle (anti-SRP) | |Signal recognition particle (anti-SRP) | ||
| | |||
| | | | ||
* Flare up in fall | * Flare up in fall | ||
| Line 59: | Line 63: | ||
|- | |- | ||
|Alanyl-tRNA synthetase (PL-12) | |Alanyl-tRNA synthetase (PL-12) | ||
| | |||
| | | | ||
* Epstein-Barr virus (EBV), adenovirus, and influenza infection | * Epstein-Barr virus (EBV), adenovirus, and influenza infection | ||
| Line 64: | Line 69: | ||
|- | |- | ||
|Transcriptional intermediary factor 1-gamma (TIF-1γ) | |Transcriptional intermediary factor 1-gamma (TIF-1γ) | ||
| | |||
| | | | ||
* Cancer-associated myositis | * Cancer-associated myositis | ||
| Line 70: | Line 76: | ||
|- | |- | ||
|Nuclear matrix protein (NXP-2) | |Nuclear matrix protein (NXP-2) | ||
| | |||
| | | | ||
* Cancer-associated myositis | * Cancer-associated myositis | ||
| Line 76: | Line 83: | ||
|- | |- | ||
|Anti-small ubiquitin-like modifier activating enzyme (anti-SAE) | |Anti-small ubiquitin-like modifier activating enzyme (anti-SAE) | ||
| | |||
| | | | ||
* Cancer-associated myositis | * Cancer-associated myositis | ||
| Line 81: | Line 89: | ||
|- | |- | ||
|Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) | |Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) | ||
| | |||
| | | | ||
* Statin-associated necrotizing autoimmune myopathy (SANAM) | * Statin-associated necrotizing autoimmune myopathy (SANAM) | ||
|6% | |6% | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||
Revision as of 16:23, 12 April 2018
|
Polymyositis and dermatomyositis Microchapters |
|
Differentiating Polymyositis and dermatomyositis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polymyositis and dermatomyositis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Polymyositis and dermatomyositis laboratory findings |
|
Polymyositis and dermatomyositis laboratory findings in the news |
|
Blogs on Polymyositis and dermatomyositis laboratory findings |
|
Risk calculators and risk factors for Polymyositis and dermatomyositis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
OR
[Test] is usually normal for patients with [disease name].
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
OR
There are no diagnostic laboratory findings associated with [disease name].
Laboratory Findings
- Different laboratory tests may be used to diagnose polymyositis and dermatomyositis and exclude other myopathies which include:[1][2]
- Sarcoplasmic enzymes
- Myositis-specific autoantibodies
Sarcoplasmic enzymes
- Sarcoplasmic enzymes consistent with the diagnosis of polymyositis and dermatomyositis include:[3]
- Creatine phosphokinase
- Aldolase
- Transaminases
- Lactic dehydrogenase
Myositis-specific autoantibodies
| Autoantibody | Antigen | Association | Percentage |
|---|---|---|---|
| Histidyl-tRNA synthetase (anti-Jo-1) |
|
||
| Chromodomain helicase DNA binding protein 4 (Mi-2) |
|
||
| Signal recognition particle (anti-SRP) |
|
||
| Alanyl-tRNA synthetase (PL-12) |
|
||
| Transcriptional intermediary factor 1-gamma (TIF-1γ) |
|
||
| Nuclear matrix protein (NXP-2) |
|
||
| Anti-small ubiquitin-like modifier activating enzyme (anti-SAE) |
|
||
| Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) |
|
6% | |
References
- ↑ Adler BL, Christopher-Stine L (February 2018). "Triggers of inflammatory myopathy: insights into pathogenesis". Discov Med. 25 (136): 75–83. PMID 29579414.
- ↑ Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllősi L, Dankó K (December 2014). "Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort". Autoimmun Rev. 13 (12): 1211–9. doi:10.1016/j.autrev.2014.08.011. PMID 25182203.
- ↑ Bohan, Anthony; Peter, James B. (1975). "Polymyositis and Dermatomyositis". New England Journal of Medicine. 292 (8): 403–407. doi:10.1056/NEJM197502202920807. ISSN 0028-4793.